comprehensive -WSS

comprehensive

author：leisure time 2025-09-29 16:46:08 - browse：4

Venture firms backing health tech startups are telegraphing cautious optimism for 2024, advising startups to expect smaller and fewer checks as well as possible market consolidation but not to abandon hope just yet as investments stabilize following a sharp drop-off.

As customers — often health systems, payers, or employers — and backers plot how they’ll invest shrinking budgets, they’re increasingly savvy about metrics, investors told STAT. They’re also less interested in rapid growth, and more keen on startups that can demonstrate savings and efficiency.

That’s a sharp contrast from the unrestrained health tech investments that peaked in 2021, fueled by a pandemic-era frenzy for virtual appointments, mental health care and app-based therapies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： The cancer drug shortage isn’t new — and neither are the solutions
Next article： How AI helped researchers track recovery from depression

WSS

Chemotherapy shortages won’t get better under Biden’s latest plan

Readout LOUD podcast: possible new ALS drug, artificial wombs

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

Biotech stock slump in 2023: awaiting the turnaround

Biotech lab space demand falls sharply

STAT Event – Decoding Clinical Trials: Venture Capitalists Talk Early Biotech R&D

hotspot

comprehensive

hotspot

In age of alternative facts, a scholarly course on calling out crap

STAT Virtual Event: Putting AI to the Test

Heart attack and stroke risk calculators need revising

Case for ALS therapy Nurown relies on ‘deficient’ data, FDA finds

Virginia high school admissions case could be legal follow

Biotech stock slump in 2023: awaiting the turnaround

The cancer drug shortage isn’t new — and neither are the solutions

FDA needs staff influx to meet gene therapy needs, Marks says

Virginia high school admissions case could be legal follow

AbbVie buys Immunogen, maker of targeted cancer drugs, for $10B

knowledge

EpiPen alternative approval delay highlights citizen petition issue

CommonSpirit Health keeps growing, even as it loses money

Microbiome research is starting to find links to chronic diseases

FDA needs staff influx to meet gene therapy needs, Marks says

Microbiome research is starting to find links to chronic diseases

The woman behind the Dana Farber

focus

entertainment

hotspot

hotspot